Ignite proteomics completes acquisition of pla code 0249u for its advanced proteomic breast cancer assay

Golden, co, feb. 19, 2025 (globe newswire) -- ignite proteomics llc, a subsidiary of imac holdings, inc. (nasdaq: back), today announced the completed transfer of proprietary laboratory analyses (pla) code 0249u – originally issued to theralink technologies, inc. – to ignite proteomics llc. the ama cpt code is listed on the medicare clinical laboratory fee schedule (clfs) and is addressed by the palmetto gba moldx “proteomics testing” article (a59636). this milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into ignite proteomics.
BACK Ratings Summary
BACK Quant Ranking